# Interim Results as of 30 September 2013

BAVARIAN NORDIC

14 November 2013

#### Financial Highlights

- Infectious Disease division remains profitable
- 5 million doses IMVAMUNE<sup>®</sup> delivered to the SNS during first nine months
- Full year financial expectations maintained

	9m 2013	9m 2012
Revenue	DKK 875m	DKK 750m
Income before tax	DKK -18m	DKK 17m
Cash preparedness	DKK 546m	DKK 666m



## Highlights from the third quarter

#### **Infectious Diseases**

- IMVANEX® received marketing authorization in Europe first product approval for the company
- Enrollment of all 4,000 subjects in the first of two U.S. Phase 3 studies of IMVAMUNE<sup>®</sup> was completed
- Deliveries of IMVAMUNE to the U.S. Strategic National Stockpile under 20m dose base contract nearly completed; now initiating deliveries under new contract

#### Cancer Immunotherapy

- PROSPECT study: 160+ sites in 13 countries now active
- Two Phase 2 studies combining PROSTVAC® and enzalutamide initiated
- Pipeline assessment and prioritization performed; CV-301 in colorectal cancer will be the next target for further clinical development



#### Short/Mid-Term Objectives


- Complete enrollment in the PROSTVAC Phase 3 trial (PROSPECT) (H1, 2014)
- Report data from NCI-sponsored clinical trials of PROSTVAC
- Prepare the Kvistgaard facility for commercial manufacturing of PROSTVAC
- Deliver 7 million doses of IMVAMUNE<sup>®</sup> to the U.S. Strategic National Stockpile in 2013
- Initiate final Phase 3 trial of IMVAMUNE<sup>®</sup>
- Decision on marketing application for IMVAMUNE<sup>®</sup> in Canada



#### Infectious Diseases

		Preclinical	Phase 1	Phase 1/2	Phase 2	Phase 3	Market
BIODEFENSE							
Smallpox	IMVANEX®						EU approved
Smallpox	IMVAMUNE®						Supplied*
Smallpox	IMVAMUNE <sup>®</sup> freeze-dried						
Anthrax	MVA-BN <sup>®</sup> Anthrax						
Filoviruses	MVA-BN <sup>®</sup> Filo						
Foot-and-mouth disease	MVA-BN <sup>®</sup> FMDV						
COMMERCIAL							
RSV	MVA-BN <sup>®</sup> RSV						
* Sold to government stock emergency rules.	piles under national						

#### **IMVAMUNE® - Anticipated Developments**



# Cancer Immunotherapy

		Preclinical	Phase 1	Phase 1/2	Phase 2	Phase 3	Market
CANCER IMMUNOTH	ERAPY						
Prostate cancer	<b>PROSTVAC®</b>						
Colorectal cancer	CV-301 colon						
Breast cancer	CV-301 breast						
Prostate cancer	MVA-BN® PRO						
Breast cancer	MVA-BN <sup>®</sup> HER2						



### **Pipeline Prioritization**

A recent assessment of the cancer immunotherapy portfolio based on preclinical and clinical results to date has led to a prioritization of pipeline opportunities:

PROSTVAC	•	Enrollment of the PROSPECT Phase 3 trial remains a top priority Combination therapy approaches in mCRPC are also being investigated
CV-301	•	Priority indication will focus on colorectal cancer Discussions with regulatory authorities on a potential larger randomized, placebo controlled trial to further evaluate the potential in this setting
MVA-BN PRO	•	Remains a strategically important element in the prostate cancer franchise, particularly as the company explores potential partnering opportunities
MVA-BN HER2	•	Promising Phase 1 data in metastatic breast cancer and a new preclinical study demonstrating potential in combination with a checkpoint inhibitor make this candidate attractive for further clinical development by the Company or a partner.




#### PROSPECT

A Randomized, Double-blind, Global Phase 3 Efficacy Trial of PROSTVAC<sup>®</sup> in Metastatic Castration-Resistant Prostate Cancer

• 13 countries active, 160+ sites


 US, Canada, Spain, UK, Iceland, Israel, Denmark, Estonia, Belgium, Russia, France, Poland, & Australia as of November, 2013

- Full enrollment anticipated in H1, 2014
- FDA approved Interim Analysis
  - Pre-specified interim analyses of data that will be performed to evaluate whether the trial should continue as planned or potentially be stopped early for efficacy or futility
  - Only marginal impact on statistical power



#### CV-301 colorectal cancer

- NCI-sponsored Phase 2 study at Duke University
- 74 patients with surgical resection and chemotherapy for metastatic colon cancer followed by CV-301 (with GM-CSF or dendritic cells)
- 161 concurrent, matched Duke control patients



#### Financial Statements

DKK million	9m 2013	9m 2012	FY 2012
Revenue	875	750	1,017
Production costs	347	379	514
Gross profit	528	371	503
Research and development costs	397	225	357
Distribution and administrative costs	137	123	177
Total operating costs	534	348	535
Income before interest and taxes (EBIT)	(6)	23	(32)
Financial income/loss	(12)	(6)	(17)
Income before company tax	(18)	17	(49)
Тах	(2)	(195)*	191*
Net profit for the period	(20)	(178)	(240)
Cash preparedness (end of period)	546	666	670

\* Tax asset was written down as of 30 June 2012 by DKK 182m due to new legislation

#### Financial Outlook

	2013
Revenue	DKK 1,100m
Income before tax	DKK 0m
Cash preparedness at year-end	DKK 600m
Assumptions:	
Deliver and revenue recognize 7 million doses of IMVAMUNE® to the U.S. Strategic National Stockpile	
R&D costs - GROUP	* DKK 570m
Infectious Disease Division, EBIT	DKK 360m
Cancer Immunotherapy Division, EBIT	DKK -325m
All numbers are approximate	

\* R&D costs include approximately DKK 110 million in contract expenses (stated under production costs in the P&L statement) as well as DKK 100 million capitalized in the balance sheet

This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.